Preview

Гипотиреоз, субклинический гипотиреоз, высоконормальный уровень ТТГ

https://doi.org/10.14341/ket2009524-16

Полный текст:

Аннотация

В обзоре обсуждаются проблемы диагностики и лечения субклинического гипотиреоза, а также референсного интервала для уровня ТТГ. Обсуждается вопрос о целесообразности изменения референсного интервала и целевого диапазона для уровня ТТГ на фоне заместительной терапии гипотиреоза.

Об авторах

A V Podzolkov



V V Fadeyev



Список литературы

1. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis // JAMA. 2002. V. 288. N 16. P. 2015–2022.

2. Althaus B.U., Staub J.J., Ryff De Leche A. et al. LDL/HDLchanges in subclinical hypothyroidism: possible risk factors for coronary heart disease // Clin. Endocrinol. 1988. V. 28. N 2. P. 157–163.

3. Baloch Z., Carayon P., Conte Devolx B. et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease // Thyroid 2003. V. 13. N 1. P. 3–126.

4. Bataille R., Klein B. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo // Arthrit. Rheumatism 1992. V. 35. N 8. P. 982–984.

5. Benson E. S. The concept of the normal range // Human pathol. 1972. V. 3. N 2. P. 152–155.

6. Benvenga S., Bartolone L., Pappalardo M.A. et al. Altered intestinal absorption of L-thyroxine caused by coffee // Thyroid. 2008. V. 18. N 3. P. 293–301.

7. Bono G., Fancellu R., Blandini F., Santoro G., Mauri M. Cognitive and affective status in mild hypothyroidism and interactions with L-thyroxine treatment // Acta Neurol. Scandinav. 2004. V. 110. N 1. P. 59–66.

8. Bottner M., Christoffel J., Rimoldi G., Wuttke W. Effects of longterm treatment with resveratrol and subcutaneous and oral estradiol administration on the pituitary-thyroid-axis // Exp. Clin. Endocrinol. Diabetes. 2006. V. 114. N 2. P. 82–90.

9. Brabant G., Beck Peccoz P., Jarzab B. et al. Is there a need to redefine the upper normal limit of TSH? European journal of endocrinology / Eur. Feder. Endocr. Societ. 2006. V. 154. N 5. P. 633–637.

10. Brabant G., Bergmann P., Kirsch C. M. et al. Early adaptation of thyrotropin and thyroglobulin secretion to experimentally decreased iodine supply in man // Metab. Clin. Experiment. 1992. V. 41. N 10. P. 1093–1096.

11. Buxton O.M., Frank S.A., L’Hermite Baleriaux M. et al. Roles of intensity and duration of nocturnal exercise in causing phase delays of human circadian rhythms // Am. J. Physio. 1997. V. 273. N 3. P. E536–542.

12. Canaris G.J., Manowitz N.R., Mayor G., Ridgway E. C. The Colorado thyroid disease prevalence study // Arch. Intern. Med. 2000. V. 160. N 4. P. 526–534.

13. Caron P., Calazel C., Parra H. J. et al. Decreased HDL cholesterol in subclinical hypothyroidism: the effect of L-thyroxine therapy // Clin. Endocrinol. 1990. V. 33. N 4. P. 519–523.

14. Christ Crain M., Meier C., Guglielmetti M. et al. Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebocontrolled trial // Atheroscler. 2003. V. 166. N 2. P. 379–386.

15. Cook D.G., Mendall M.A., Whincup P.H. et al. C-reactive protein concentration in children: relationship to adiposity and other cardiovascular risk factors // Atheroscler. 2000. V. 149. N 1. P. 139–150.

16. Cooper D.S., Halpern R., Wood L.C. et al. L-Thyroxine therapy in subclinical hypothyroidism. A double-blind, placebo-controlled trial // Ann. Intern. Med. 1984. V. 101. N 1. P. 18–24.

17. Cushing G.W. Subclinical hypothyroidism. Understanding is the key to decision making // Postgrad. Med. 1993. V. 94. N 1. P. 95–97, 100–102, 106–107.

18. Custro N., Scafidi V., Lo Baido R. et al. A. Subclinical hypothyroidism resulting from autoimmune thyroiditis in female patients with endogenous depression // J. Endocrinol. Iinvestig. 1994. V. 17. N 8. P. 641–646.

19. Cтроев Е.А., Касаткина Э.П., Дмитриева Н.В., Филимоно ва А.Ю. Состояние липидного обмена и гормонального статуса у больных сахарным диабетом I типа в сочетании с субклиническим гипотиреозом // Пробл. эндокринол. 1996. V. 4. P. 9–11.

20. d’Herbomez M., Jarrige V., Darte C. Reference intervals for serum thyrotropin (TSH) and free thyroxine (FT4) in adults using the Access Immunoassay System // Clin. Chem. Lab. Med. 2005. V. 43. N 1. P. 102–105.

21. Danese M.D., Powe N.R., Sawin C.T., Ladenson P.W. Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness analysis // Jama. 1996. V. 276.N 4. P. 285–292.

22. Danesh J., Whincup P., Walker M., Lennon L., Thomson A., Appleby P., Gallimore J.R., Pepys M.B. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses // B.M.J. 2000. V. 321. N 7255. P. 199–204.

23. Davis J.D., Tremont G. Neuropsychiatric aspects of hypothyroidism and treatment reversibility // Minerva Endocrinol. 2007. V. 32. N 1. P. 49–65.

24. Diez J.J., Iglesias P., Burman K.D. Spontaneous normalization of thyrotropin concentrations in patients with subclinical hypothyroidism // J. Clin. Endocrinol. Metab. 2005. V. 90. N 7. P. 4124–4127.

25. Elmlinger M.W., Kuhnel W., Lambrecht H.G., Ranke M.B. Reference intervals from birth to adulthood for serum thyroxine (T4), triiodothyronine (T3), free T3, free T4, thyroxine binding globulin (TBG) and thyrotropin (TSH) // Clin. Chem. Lab. Med. 2001. V. 39. N 10. P. 973–979.

26. Ford E.S., Giles W.H. Serum C-reactive protein and self-reported stroke: findings from the Third National Health and Nutrition Examination Survey // Arterioscleros. Thrombos. Vascul. Biol. 2000. V. 20. N 4. P. 1052–1056.

27. Fu W.Y., Dudman N.P., Perry M.A., Wang X.L. Homocysteine attenuates hemodynamic responses to nitric oxide in vivo // Atheroscleros. 2002. V. 161. N 1. P. 169–176.

28. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation // N. England J. Med. 1999. V. 340. N 6. P. 448–454.

29. Genser D., Prachar H., Hauer R. et. Relation of homocysteine, vitamin B(12), and folate to coronary in-stent restenosis // Am. J. Cardiol. 2002. V. 89. N 5. P. 495–499.

30. Glass CK., Witztum JL. Atherosclerosis. the road ahead // Cell. 2001. V. 104. N 4. P. 503–516.

31. Graham I.M., Refsum H.M., Robinson K. et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project // JAMA. 1997. V. 2. (77). N 22. P. 1775–1781.

32. Gulseren S., Gulseren L., Hekimsoy Z. et al. Depression, anxiety, health-related quality of life, and disability in patients with overt and subclinical thyroid dysfunction // Archiv. Medic. Research. 2006. V. 37. N 1. P. 133–139.

33. Gupta A., Sinha R.S. Echocardiographic changes and alterations in lipid profile in cases of subclinical and overt hypothyroidism // J. Associat. Physic. India. 1996. V. 44. N 8. P. 546, 551–553.

34. Gursoy A., Ozduman Cin M., Kamel N., Gullu S. Which thyroidstimulating hormone level should be sought in hypothyroid patients under L-thyroxine replacement therapy? // Internat. J. Clin. Pract. 2006. V. 60. N 6. P. 655–659.

35. Haggerty J.J., Garbutt J.C., Evans D.L. et al. Subclinical hypothyroidism: a review of neuropsychiatric aspects // Internat. J. Psych. Med. 1990. V. 20. N 2. P. 193–208.

36. Haggerty J.J., Stern R.A., Mason G.A. et al. Subclinical hypothyroidism: a modifiable risk factor for depression? // Am. J. Psych. 1993. V. 150. N 3. P. 508–510.

37. Hamilton T.E., Davis S., Onstad L., Kopecky K.J. Thyrotropin levels in a population with no clinical, autoantibody, or ultrasonographic evidence of thyroid disease: implications for the diagnosis of subclinical hypothyroidism // J. Clin. Endocrinol. Metab. 2008. V. 93. N 4. P. 1224–1230.

38. Hansen P.S., Brix T.H., Sorensen T.I. et al. Major genetic influence on the regulation of the pituitary-thyroid axis: a study of healthy Danish twins // J. Clin. Endocrinol. Metab. 2004. V. 89. N 3. P. 1181–1187.

39. Harris T.B., Ferrucci L., Tracy R.P. et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly // Am. J. Med. 1999. V. 106. N 5. P. 506–512.

40. Hayden M.R., Tyagi S.C. Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: the pleiotropic effects of folate supplementation // Nutrit. J. 2004. V. 3. P. 4.

41. Henny J. The IFCC recommendations for determining reference intervals: strengths and limitations // Laborator. Med. 2009. V. 33. N 2. P. 45–51.

42. Hollowell J.G., Staehling N.W., Flanders W.D. et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III) // J. Clin. Endocrinol. Metab. 2002. V. 87. N 2. P. 489–499.

43. Howland R.H. Thyroid dysfunction in refractory depression: implications for pathophysiology and treatment // J. Clin. Psych. 1993. V. 54. N 2. P. 47–54.

44. Jensen E., Hyltoft–Petersen P., Blaabjerg O. et al. Establishment of a serum thyroid stimulating hormone (TSH) reference interval in healthy adults. The importance of environmental factors, including thyroid antibodies // Clin. Chem. Lab. Med. 2004. V. 42. N 7. P. 824–832.

45. Jensovsky J., Ruzicka E., Spackova N., Hejdukova B. Changes of event related potential and cognitive processes in patients with subclinical hypothyroidism after thyroxine treatment // Endocrin. Regulat. 2002. V. 36. N 3. P. 115–122.

46. Joffe R.T., Levitt A.J. Major depression and subclinical (grade 2) hypothyroidism // Psychoneuroendocrinol. 1992. V. 17. N 2–3. P. 215–221.

47. Kahaly G.J. Cardiovascular and atherogenic aspects of subclinical hypothyroidism // Thyroid. 2000. V. 10. N 8. P. 665–679.

48. Karmisholt J., Andersen S., Laurberg P. Interval between tests and thyroxine estimation method influence outcome of monitoring of subclinical hypothyroidism // J. Clin. Endocrinol. Metab. 2008. V. 93. N 5. P. 1634–1640.

49. Karmisholt J., Andersen S., Laurberg P. Variation in thyroid function tests in patients with stable untreated subclinical hypothyroidism // Thyroid. 2008. V. 18. N 3. P. 303–308.

50. Knudsen N., Bulow I., Jorgensen T. et al. Comparative study of thyroid function and types of thyroid dysfunction in two areas in

51. ГИПОТИРЕОЗ, СУБКЛИНИЧЕСКИЙ ГИПОТИРЕОЗ.. А.В. Подзолков и соавт. Denmark with slightly different iodine status // Eur. J. Endocrinol. Eur. Federat. Endocr. Societ. 2000. V. 143. N 4. P. 485–491.

52. Knudsen N., Laurberg P., Rasmussen L.B. et al. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population // J. Clin. Endocrinol. Metab. 2005. V. 90. N 7. P. 4019–4024.

53. Koenig W., Sund M., Frohlich M. et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992 // Circulat. 1999. V. 99. N 2. P. 237–242.

54. Kraus R.P., Phoenix E., Edmonds M.W. et al. Exaggerated TSH responses to TRH in depressed patients with “normal” baseline TSH // J. Clin. Psych. 1997. V. 58. N 6. P. 266–270.

55. Kung A.W., Pang R.W., Janus E.D. Elevated serum lipoprotein(a) in subclinical hypothyroidism // Clin. Endocrinol. 1995. V. 43. N 4. P. 445–449.

56. Laryea E.A. Subclinical hypothyroidism. To treat or not to treat // Canad. Family Pphys. Med. Famil. Canad. 1993. V. 39. P. 1997–1998, 2001–1993.

57. Lekakis J., Papamichael C., Alevizaki M. et al. Flow-mediated, endothelium-dependent vasodilation is impaired in subjects with hypothyroidism, borderline hypothyroidism, and high-normal serum thyrotropin (TSH) values // Thyroid. 1997. V. 7. N 3. P. 411–414.

58. Lilja J.J., Laitinen K., Neuvonen P.J. Effects of grapefruit juice on the absorption of levothyrroxine // Brit. J. Clin. Pharmacol. 2005. V. 60. N 3. P. 337–341.

59. Luboshitzky R., Aviv A., Herer P., Lavie L. Risk factors for cardiovascular disease in women with subclinical hypothyroidism // Thyroid. 2002. V. 12. N 5. P. 421–425.

60. Luboshitzky R., Herer P. Cardiovascular risk factors in middle-aged women with subclinical hypothyroidism // Neur. Endocrinol. Letters. 2004. V. 25. N 4. P. 262–266.

61. Malvano R., Chiecchio A., Borsa M., Messeri G. The uncertainty associated with the predictive value of test results // Clin. Chem. Lab. Med. 1998. V. 36. N 7. P. 463–468.

62. Margaglione M., Cappucci G., Colaizzo D. et al. C-reactive protein in offspring is associated with the occurrence of myocardial infarction in first-degree relatives // Arterioscleros.Thrombos. Vascul. Bbiol. 2000. V. 20. N 1. P. 198–203.

63. Mayer E.L., Jacobsen D.W., Robinson K. Homocysteine and coronary atherosclerosis // J. Am. Colleg. Cardiol. 1996. V. 27. N 3. P. 517–527.

64. Mazokopakis E.E., Chatzipavlidou V. Hashimoto’s thyroiditis and the role of selenium. Current concepts //Hellen. J. Nucl. Med.2007. V. 10. N 1. P. 6–8.

65. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis // Am. J. Pathol. 1969. V.56. N 1. P. 111–128.

66. Mendall M.A., Strachan D.P., Butland B.K. et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men // Eur. Heart J. 2000. V. 21. N 19. P. 1584–1590.

67. Meyerovitch J., Rotman Pikielny P., Sherf M. et al. Serum thyrotropin measurements in the community: five-year follow-up in a large network of primary care physicians // Arch. Internal. Med. 2007. V. 167. N 14. P. 1533–1538.

68. Miller M.J., Pan C., Barzel U.S. The prevalence of subclinical hypothyroidism in adults with low-normal blood thyroxine levels // N.-Y. Stat. J. Med. 1990. V. 90. N 11. P. 541–544.

69. Moat S.J., Lang D., McDowell I.F., Clarke Z. L. et al. Folate, homocysteine, endothelial function and cardiovascular disease // J. Nutrition. Biochemistr. 2004. V. 15. N 2. P. 64–79.

70. Monzani F., Del Guerra P., Caraccio N. et al. Subclinical hypothyroidism: neurobehavioral features and beneficial effect of L-thyroxine treatment // Clin. investigat. 1993. V. 71. N 5. P. 367–371.

71. Moshal K.S., Camel C.K., Kartha G.K. et al. Cardiac dys-synchronization and arrhythmia in hyperhomocysteinemia // Current. Neurovascul. Research 2007. V. 4. N 4. P. 289–294.

72. Nakagomi A., Freedman S.B., Geczy C.L. Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, and hormone replacement treatment // Circulat. 2000. V. 101. N 15. P. 1785–1791.

73. Nystrom E., Caidahl K., Fager G. et al. A double-blind cross-over 12-month study of L-thyroxine treatment of women with ‘subclinical’ hypothyroidism // Clin. Endocrino. 1988. V. 29. N 1. P. 63–75.

74. Parle J.V., Maisonneuve P., Sheppard M.C. et al. Prediction of allcause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study // Lancet. 2001. V. 358. N 9285. P. 861–865.

75. Ponte E., Ursu H.I. Overt and subclinical hypothyroidism and atherosclerotic arteriopathy of the lower limbs (clinical and subclinical) // Roman. J. Endocrinol. 1993. V. 31. N 1–2. P. 71–79.

76. Ridker P.M. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease // Circulat. 2001. V. 103. N 13. P. 1813–1818.

77. Romijn J.A., Smit J.W., Lamberts S.W. Intrinsic imperfections of endocrine replacement therapy // Eur. J.Endocrinol. 2003. V. 149. N 2. P. 91–97.

78. Ross R. Atherosclerosis is an inflammatory disease // Am. Heart J. 1999. V. 138. N 5 (Pt. 2). P. S419–420.

79. Ross R. Atherosclerosis—an inflammatory disease // N. Eng. J. Med. 1999. V. 340. N 2. P. 115–126.

80. Samuels M.H. Subclinical thyroid disease in the elderly // Thyroid 1998. V. 8. N 9. P. 803–813.

81. Sawin C.T. Subclinical hypothyroidism in older persons // Clin. Geriatr. Med. 1995. V. 11. N 2. P. 231–238.

82. Selhub J., Jacques P.F., Bostom A.G. et al. Relationship between plasma homocysteine, vitamin status and extracranial carotidartery stenosis in the Framingham Study population // J. Nnutrit. 1996. V. 126. N 4. P. 1258S–1265S.

83. Selhub J., Jacques P.F., Bostom A.G. et al. Relationship between plasma homocysteine and vitamin status in the Framingham study population. Impact of folic acid fortification // Public. Health Reviews. 2000. V. 28. N 1–4. P. 117–145.

84. Shastry S., Tyagi N., Hayden M.R., Tyagi S.C. Proteomic analysis of homocysteine inhibition of microvascular endothelial cell angiogenesis // Cell. Molecul. Bbiol. (Noisy-le-Grand, France) 2004. V. 50. N 8. P. 931–937.

85. Solberg H.E. International Federation of Clinical Chemistry (IFCC), Scientific Committee, Clinical Section, Expert Panel on Theory of Reference Values, and International Committee for Standardization in Haematology (ICSH), Standing Committee on Reference Values. Approved Recommendation (1986) on the theory of reference values. Part 1. The concept of reference values // J. Clin. Chem. Clin. Biochem. 1987. V. 25. N 5. P. 337–342.

86. Solberg H.E. International Federation of Clinical Chemistry. Scientific committee, Clinical Section. Expert Panel on Theory of Reference Values and International Committee for Standardization in Haematology Standing Committee on Reference Values. Approved recommendation (1986) on the theory of reference values. Part 1. The concept of reference values // Internation. J. Clin. Chemistr. 1987. V. 165. N 1. P. 111–118.

87. Spielhagen C.B.K., Krebs A., Wallaschofski H. Reference values for thyroid function tests during pregnancy // Labor. Med. 2009. V. 33. N 1.

88. Stampfer M. J., Malinow M.R. Can lowering homocysteine levels reduce cardiovascular risk? // N. Engl. J. Med. 1995. V. 332. N 5. P. 328–329.

89. Strandberg T.E., Tilvis R.S. C-reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly // Arterioscler. Thrombos. Vascul. Biol. 2000. V. 20. N 4. P. 1057–1060.

90. Surks M.I., Goswami G., Daniels G.H. The thyrotropin reference range should remain unchanged // J. Clin. Endocrinol. Metab. 2005. V. 90. N 9. P. 5489–5496.

91. Surks M.I., Ortiz E., Daniels G.H. et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management / JAMA. 2004. V. 291. N 2. P. 228–238.

92. Tawakol A., Omland T., Gerhard M. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans // Circulat. 1997. V. 95. N 5. P. 1119–1121.

93. Toruner F., Altinova A.E., Karakoc A. et al. Risk factors for cardiovascular disease in patients with subclinical hypothyroidism //.Advanc. Therapy. 2008. V. 25. N 5. P. 430–437.

94. Torzewski M., Rist C., Mortensen R.F. et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis // Arterioscleros. Thrombos. Vascul. Biol. 2000. V. 20. N 9. P. 2094–2099.

95. Turhan S., Sezer S., Erden G., Guctekin A. et al. Plasma homocysteine concentrations and serum lipid profile as atherosclerotic risk factors in subclinical hypothyroidism // Ann. Saudi Med. 2008. V. 28. N 2. P. 96–101.

96. Tyagi N., Moshal K.S., Lominadze D. Homocysteine-dependent cardiac remodeling and endothelial-myocyte coupling in a 2 kidney, 1 clip Goldblatt hypertension mouse model // Canad. J. Physiol. Pharmacol. 2005. V. 83. N 7. P. 583–594.

97. Vanderpump MP., Tunbridge W.M., French J.M. et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey // Clin. Endocrinol. 1995. V. 43. N 1. P. 55–68.

98. Vanhaelst L., Neve P., Chailly P., Bastenie P. A. Coronary-artery disease in hypothyroidism. Observations in clinical myxoedema // Lancet. 1967. V. 2. N 7520. P. 800–802.

99. Volzke H., Alte D., Kohlmann T. et al. Reference intervals of serum thyroid function tests in a previously iodine-deficient area // Thyroid. 2005. V. 15. N 3. P. 279–285.

100. Volzke H., Robinson D.M., Schminke U. et al. Thyroid function and carotid wall thickness // J. Clin. Endocrinol. Metab. 2004. V. 89. N 5. P. 2145–2149.

101. Volzke H., Robinson D.M., Spielhagen T. et al. Are serum thyrotropin levels within the reference range associated with endothelial function? // Eur. Hheart J. 2009. V. 30. N 2. P. 217–224.

102. Walsh J.P., Ward L.C., Burke V. et al. Small changes in thyroxine dosage do not produce measurable changes in hypothyroid symptoms, well-being, or quality of life: results of a double-blind, randomized clinical trial // J. Clin. Endocrinol. Mmetab. 2006. V. 91. N 7. P. 2624–2630.

103. Wang X.L., Duarte N., Cai H. et al. Relationship between total plasma homocysteine, polymorphisms of homocysteine metabolism related enzymes, risk factors and coronary artery disease in the Australian hospital-based population // Atheroscleros. 1999. V. 146. N 1. P. 133–140.

104. Wartofsky L., Dickey R.A. The evidence for a narrower thyrotropin reference range is compelling // J. Clin. Endocrinol. Metab. 2005. V. 90. N 9. P. 5483–5488.

105. Weir D.G., Scott J.M. Homocysteine as a risk factor for cardiovascular and related disease: nutritional implications // Nutrit. Research Reviews 1998. V. 11. N 2. P. 311–338.

106. Wekking E.M., Appelhof B.C., Fliers E. et al. Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for primary hypothyroidism. European journal of endocrinology // Eur. Federat. Endocr. Societ. 2005. V. 153. N 6. P. 747–753.

107. Woods A., Brull D.J., Humphries S.E., Montgomery H.E. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6 // Eur. Heart J. 2000. V. 21. N 19. PP. 1574–1583.

108. Zwaka T.P., Hombach V., Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis // Circulation 2001. V. 103. N 9. P. 1194–1197.

109. Верткин А.Л. Проблема гипергомоцистеинемии у кардиологических больных // Фарматека. 2007. № 15. С. 10–14.

110. Воронцов В.Л., Смирнова О.И. Особенности течения атеросклероза у больных, страдающих гипотиреозом // Клин. вестн.1997. № 2. С. 64–67.

111. Дедов И.И., Мельниченко Г.А., Фадеев В.В. Эндокринология / Учебник для студ. мед. вузов. М.: Медицина, 2000.

112. Костюченко Г.И. Диагностика и методы коррекции гипергомоцистеинемии в кардиологической практике / Пособие для врачей. М., 2003.

113. Панченкова Л.А., Трошина Е.В., Юркова Т.Н. Особенности кардиологического статуса больных ИБС с наличием субклинического гипотиреоза. Компьютерная электрокардиография на рубеже столетий XX–XXI. М., 1999. С. 39–41.

114. Сеидова Г.Б. С-реактивный белок и его связь с метаболическим синдромом, ассоциированным с ишемической болезнью сердца у женщин в преи постменопаузе // Вест. аритмол. 2005. № 41. С. 47–50.

115. Спирин Н.Н., Александров Ю.К., Касаткина Е.Л. Неврологические аспекты нарушения функции щитовидной железы. Ярославль: Редмер, 2007.

116. Фадеев В.В. Нормативы уровня ТТГ: нужны ли изменения? // Клин. и эксперим. тиреоидол. 2004. № 3. С. 5–9.

117. Фадеев В.В., Мельниченко Г.А. Гипотиреоз / Руководство для врачей. М.: РКИ “Северо-пресс”, 2002. 216 c.


Для цитирования:


Podzolkov A.V., Fadeyev V.V. Гипотиреоз, субклинический гипотиреоз, высоконормальный уровень ТТГ. Клиническая и экспериментальная тиреоидология. 2009;5(2):4-16. https://doi.org/10.14341/ket2009524-16

For citation:


., . Hypothyroidism, Subclinical Hypothyroidism, High-normal TSH-level. Clinical and experimental thyroidology. 2009;5(2):4-16. (In Russ.) https://doi.org/10.14341/ket2009524-16

Просмотров: 155


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-5472 (Print)
ISSN 2310-3787 (Online)